Relmada Therapeutics Inc (RLMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.43+1.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RLMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RLMD — earnings miss
Dated 2026-05-12
Results of Operations and Financial Condition. On May 12, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the three months ended March 31, 2026. The Company also announced that it would conduct a conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete unaudited condensed consolidated financial statements and no…
Why it matters: Updates on the Phase 2 trials will show progress in a key growth area for the company.
Supportive ifA press release shows good results from the Phase 2 trials.
Worry ifNo updates or negative results reported from the Phase 2 trials.
Why it matters: Starting this program is a key milestone for Relmada. It shows progress in treating bladder cancer.
Supportive ifThe Phase 3 RESCUE program for NDV-01 is initiated in mid-2026 as planned.
Worry ifThe initiation of the Phase 3 RESCUE program is delayed past mid-2026.
Why it matters: Watching cash burn is important for knowing financial health and how the company runs.
Worry ifNet cash used in operating activities is lower than in Q2 2026.
Less concerning ifNet cash used in operating activities is higher than in Q2 2026.
Why it matters: This study shows how well sepranolone can treat Prader-Willi Syndrome.
Supportive ifThe company starts the Phase 2 study for sepranolone after getting IND clearance.
Worry ifThe Phase 2 study for sepranolone is delayed or not initiated.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$174 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $776 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,491 loss on $10,000 · 44.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Raising money is important. It helps fund operations and clinical trials.
Supportive ifA private placement raised more than $10M successfully.
Worry ifNo announcement or failure to raise capital as planned.
Why it matters: Earnings results will show how well the company is doing financially.
Watch forEarnings report shows revenue growth or reduced cash burn.
Also watch forEarnings report shows continued losses and high cash burn.
Why it matters: Earnings results will show financial health and operational progress. A miss could hurt stock price.
Watch forEarnings were better than expected. This shows good financial results.
Also watch forEarnings were worse than expected. This shows ongoing financial problems.
Why it matters: If granted, this patent could help NDV-01 in the market. It would also extend its exclusivity.
Supportive ifThe USPTO grants the provisional patent for NDV-01.
Worry ifThe patent application may be rejected or delayed.
Why it matters: Filing the IND is crucial for starting the Phase 3 RESCUE program. It shows progress in NDV-01's development.
Supportive ifThe IND for NDV-01 is submitted by December 31, 2026.
Worry ifThe IND filing is delayed beyond year-end 2026.
Why it matters: Starting the Phase 3 program is a key milestone for NDV-01. It indicates readiness for broader clinical trials.
Supportive ifThe Phase 3 RESCUE program begins within 3 months of IND clearance.
Worry ifThe Phase 3 RESCUE program does not start within 6 months of IND clearance.
Why it matters: Managing cash burn is vital for funding operations. A decrease in cash burn indicates better financial health.
Watch forNet cash used in operations goes down for two quarters in a row.
Also watch forNet cash used in operations goes up for two quarters in a row.